New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease . Crohn 's disease is a T helper type 1 response immune disease characterized by increased production of interleukin-12 tumor necrosis factor-a ( P01375 ) , and interferon-g . Clinical trials have demonstrated that inhibition of P01375 is effective for the treatment of Crohn 's disease . Adverse events reported in patients treated with anti- P01375 agents include immunogenicity , acute infusion reactions , delayed hypersensitivity-type reactions , autoimmune diseases including drug-induced lupus and demyelination , and infection . This article reviews new concepts in the treatment of Crohn 's disease and ulcerative colitis with a variety of anti- P01375 biologic therapies : infliximab , adalimumab , DB08904 , CDP571 , etanercept , and onercept .